---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-273298"
form_type: "8-K/A"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:51:23.234142+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha grants Astellas options for GAN/Rett programs; $20M upfront + $30M equity raise

## Summary
- Astellas gets exclusive options to license TSHA-120 (GAN) and TSHA-102 (Rett) post specified clinical/regulatory milestones.
- Upfront payment of $20M from Astellas; $30M private placement of 7.27M shares of common stock at ~$4.13/share.
- TSHA-120 Type B end-of-Phase 2 FDA meeting scheduled Dec 13, 2022; update expected mid-Jan 2023.
- TSHA-102 preliminary safety/efficacy data for adult cohort now expected H1 2023 (delayed from year-end 2022); female pediatric trial to start H1 2023.
- Taysha agrees to change-of-control restrictions during Rett option period; Astellas receives board observer right.

## SEC filing metadata
- accession: 0001193125-22-273298
- form_type: 8-K/A
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/d395338d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-273298
- JSON: https://secwatch.observer/filing/0001193125-22-273298.json
- Plain text: https://secwatch.observer/filing/0001193125-22-273298.txt

## Key facts
- Material Agreements
  Taysha Gene Therapies, Inc. entered into Option Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas") valued at $20.0 million (effective 2022-10-21).
  - Action: entry
  - Agreement: license
  - Counterparty: Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas")
  - Value: $20.0 million
  - Effective: 2022-10-21
  source text: On October 21, 2022 (the “Effective Date”), Taysha Gene Therapies, Inc. (the “Company”) entered into an Option Agreement (the “Option Agreement”) with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (“Astellas”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm
- Material Agreements
  Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas") valued at approximately $30.0 million (effective 2022-10-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas")
  - Value: approximately $30.0 million
  - Effective: 2022-10-21
  source text: On October 21, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Astellas, pursuant to which the Company agreed to issue and sell to Astellas in a private placement (the “Private Placement”) an aggregate of 7,266,342 shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522273298/0001193125-22-273298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.